Obstetrx
Obstetrx is developing a uterine tamponade device that utilizes clinically-proven battlefield technology to provide rapid and effective treatment for postpartum hemorrhage. This device addresses the critical issue of maternal mortality by delivering timely intervention to prevent excessive blood loss during childbirth.
- Hardware
- Healthcare Technology
- Medical Devices
Funding
Raised to date
$4.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Postpartum hemorrhage (PPH), often caused by uterine atony, is a leading cause of maternal mortality worldwide, impacting millions of women annually. Current methods for treating PPH can be difficult to use and slow to deploy, leading to delays in critical intervention. In the US, the incidence of PPH is increasing, highlighting the need for more effective and accessible solutions.
Solution
Obstetrx is developing a novel medical device designed to provide rapid and effective uterine tamponade for the treatment of postpartum hemorrhage. The device adapts clinically-proven battlefield technology for use in the delivery room, offering a simple, fast, and effective solution to control bleeding. By addressing uterine atony, the device aims to reduce maternal deaths and disabilities associated with PPH. The device is designed to be easy to use, enabling timely intervention in situations where every minute counts.
Target Audience
The primary target audience includes obstetricians, gynecologists, hospitals, and birthing centers seeking effective solutions for managing postpartum hemorrhage and reducing maternal mortality.
Features
- Uterine tamponade device based on clinically-proven battlefield technology
- Designed for rapid deployment and ease of use in postpartum hemorrhage scenarios
- Addresses uterine atony, a primary cause of postpartum hemorrhage